Defence Therapeutics, a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, has just completed a pre-clinical study using it’s intranasal formulation of AccuTOXTM in the context of animals with pre-established lung cancer.
The study shows that AccuTOXTM administration as a combination therapy with the immune-checkpoint inhibitor anti-PD1 dramatically reduces the level of lung nodules compared to control non-treated or anti-PD1-treated animals.
This 50% reduction of cancer nodules on animals with pre-established lung tumours was achieved in a treatment plan of only six administrated doses over two weeks with the AccuTOXTM anti-PD1 combination.
AccuTOXTM as a pleiotropic anti-cancer treatment
The AccuTOXTM molecule was originally designed to exhibit enhanced anti-tumoural properties compared to the original AccumTM molecule. In fact, the IC50 of AccuTOXTM is 30-fold lower than that of AccumTM clearly demonstrating improved therapeutic potency as shown using a large set of murine and human tumours. This is exemplified by the enhanced therapeutic potency of the compound when directly injected in solid tumours in combination with various immune-checkpoints (anti-PD-1, anti-CTLA4 and anti-CD47).
The sum of these results paved the path to test the compound in another animal model of pre-established lung cancer delivered via the intranasal route. For that purpose, a series of maximum tolerated dose (MTD) studies were conducted to identify the volume, dosage and tolerance of mice to repetitive administration of AccuTOXTM.
These studies show that AccuTOXTM is well tolerated up to three mg/kg (five to six times lower than the injectable dose) with a regimen of six administrations over two weeks. When tested using this schedule on animals with lung tumours, AccuTOXTM decreased by over 50% the number of cancer nodules especially in the group combined with the anti-PD1 immune-checkpoint inhibitor.
“We are very pleased with the versatile use of AccuTOXTM as a cancer therapeutic. The compound has not only shown great potential in treating solid tumours, but we have now data demonstrating that it can be further adapted and delivered via the intranasal route to treat lungs with metastatic tumours which is a new hope for lung cancer patients,” said Mr Plouffe, the CEO of Defence Therapeutics.
“And this will open-up a completely new horizon for AccuTOXTM as an anti-cancer treatment”, he adds. The global lung cancer therapeutics market size was estimated at USD 27.57 billion in 2021 and it is expected to surpass around USD 55.6 billion by 2030 with a registered CAGR of 8.11% from 2022 to 2030 according to Precedence Research.
The AccuTOXTM program is one of Defence’s most advanced immune-oncology programs. The Company is currently preparing for it’s FDA meeting to obtain approval for initiating a Phase I trial against solid tumours in 2023. By demonstrating great safety and tolerability profiles in patients, AccuTOXTM can become the next-generation anti-cancer treatment for a wide range of indications.
Here is a link to a related video https://www.youtube.com/watch?v=Kgd2fUGP3BU
Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation of vaccines and ADC products using it’s proprietary platform. The core of Defence Therapeutics platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illnesses such as cancer and infectious diseases.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272